Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
about
Cardiometabolic Syndrome and Increased Risk of Heart FailureEffect of sitagliptin on the echocardiographic parameters of left ventricular diastolic function in patients with type 2 diabetes: a subgroup analysis of the PROLOGUE study.Low circulating pentraxin 3 levels in pregnancy is associated with gestational diabetes and increased apoB/apoA ratio: a 5-year follow-up studyCardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up.Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE studyAcute hyperglycemia suppresses left ventricular diastolic function and inhibits autophagic flux in mice under prohypertrophic stimulationMeta-analysis and critical review on the efficacy and safety of alpha glucosidase inhibitors in Asian and non-Asian populations.Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials.Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms.Practical strategies for improving outcomes in T2DM: The potential role of pioglitazone and DPP4 inhibitors.Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.Circulating pentraxin 3 is positively associated with chronic hyperglycemia but negatively associated with plasma aldosterone concentration.Effects of oral antidiabetic drugs on left ventricular mass in patients with type 2 diabetes mellitus: a network meta-analysis
P2860
Q28070075-435A10D6-1A0A-4F81-A284-44BFAF414D7FQ33660548-F46B6396-9407-4622-AE83-C9E322F33AF3Q36538797-03E78B15-B38B-4035-A62A-D6441CB9E84EQ36758314-4CEF0A71-2C7D-46CC-B01A-BB8BEA728BBCQ37254915-34FB22AC-0749-4A16-9E8B-B698A0549FF8Q37278532-9C348EC6-1AF9-4444-B2E3-70B1CFEB3F84Q39420555-B319D532-3F2B-42FF-B825-45BDEFDFD274Q41107105-30166112-4C70-48CA-A1E6-B13995687743Q42379243-7F754B30-87D9-4DED-B67E-F1C21F3BDB93Q43826855-B1A166F6-0BCD-427E-A4D5-5A001A85FDC6Q47697775-784B47C9-E1D0-4B3B-91DA-ADC8E142A056Q48043450-23DDE613-6582-46E8-AD44-C0BD9C0C05BDQ55223194-61CB6B8D-10EF-4029-BECB-1C4A24906C27Q58691975-5CCDE839-B442-4AD5-A250-C160D167C391
P2860
Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Comparison of effects of sitag ...... etes: results of the 3D trial.
@ast
Comparison of effects of sitag ...... etes: results of the 3D trial.
@en
type
label
Comparison of effects of sitag ...... etes: results of the 3D trial.
@ast
Comparison of effects of sitag ...... etes: results of the 3D trial.
@en
prefLabel
Comparison of effects of sitag ...... etes: results of the 3D trial.
@ast
Comparison of effects of sitag ...... etes: results of the 3D trial.
@en
P2093
P2860
P1476
Comparison of effects of sitag ...... etes: results of the 3D trial.
@en
P2093
FESC, for Effect of a DPP-4 in ...... pathy (3D) study investigators
Hajime Kihara
Hiroshi Ito
Junichi Yoshikawa
Kazufumi Nakamura
Kenei Shimada
Kumiko Hirata
Shota Fukuda
Toru Miyoshi
P2860
P2888
P356
10.1186/S12933-015-0242-Z
P407
P577
2015-06-19T00:00:00Z
P5875
P6179
1024056200